Clair Emerges to Build Hormone-Tracking Wearable
Clair, a new longevity-focused startup, has emerged from stealth with plans to launch a continuous, non-invasive hormone-tracking wearable. The device aims to provide real-time, needle-free hormonal insights. The product targets the growing interest in personalized health data for both chronic condition management and wellness optimization.
- The company was founded by Stanford graduates Jenny Duan and Abhinav Agarwal, who met in the spring of 2025 and began developing the technology. - Clair's wrist-worn device utilizes multimodal sensing, combining data from 10 biosensors that track over 500 biomarkers—including skin temperature, heart rate variability, and electrodermal activity—to infer hormone patterns. - To address privacy concerns, all data processing is designed to happen directly on the user's phone rather than being sent to external data centers, limiting third-party access to sensitive health information. - The company plans to pursue FDA approval to position the wearable as a medically credible device and is preparing for a clinical trial at Stanford Medicine. - The wearable aims to track levels of key hormones including estrogen, progesterone, LH, and FSH to provide insights for fertility, perimenopause, athletic performance, and managing hormonal health conditions. - Clair enters a competitive landscape of startups developing non-invasive hormone tracking, including Eli Health which uses at-home saliva tests and Oova which uses AI to analyze urine test strips. - The global femtech market, which Clair is a part of, was valued at over USD 9 billion in 2025 and is projected to grow to more than USD 41 billion by 2034. - Venture capital firm Reach Capital is an investor in the company, citing the need for tools that can capture and interpret hormonal data continuously and non-invasively.
